NCT02486952View on ClinicalTrials.gov

MabThera (Rituximab) in Combination With CHOP (or CHOP-like) Chemotherapy in Patients With Aggressive B-Cell Lymphoma

CompletedOBSERVATIONAL
Enrollment

154

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

January 31, 2011

Study Completion Date

January 31, 2011

Conditions
Lymphoma, Lymphoma, Large B-Cell, Diffuse, Non-Hodgkin's Lymphoma, Lymphoma, Non Hodgkin, Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Interventions
DRUG

Cyclophosphamide

Administered at the treating physician's discretion and according to package labeling, within approved indication and local approval status of the drug.

DRUG

Hydroxydaunorubicin

Administered at the treating physician's discretion and according to package labeling, within approved indication and local approval status of the drug.

DRUG

Oncovin

Administered at the treating physician's discretion and according to package labeling, within approved indication and local approval status of the drug.

DRUG

Prednisone

Administered at the treating physician's discretion and according to package labeling, within approved indication and local approval status of the drug.

DRUG

Rituximab

Administered at the treating physician's discretion and according to package labeling, within approved indication and local approval status of the drug.

Trial Locations (5)

11000

Belgrade

11070

Belgrade

18000

Niš

21204

Kamenitz

34000

Kragujevac

All Listed Sponsors
collaborator

Serbian Lymphoma Group

UNKNOWN

lead

Hoffmann-La Roche

INDUSTRY

NCT02486952 - MabThera (Rituximab) in Combination With CHOP (or CHOP-like) Chemotherapy in Patients With Aggressive B-Cell Lymphoma | Biotech Hunter | Biotech Hunter